- Home
- SGMT vs XGN Comparison
SGMT vs XGN Comparison
Compare SGMT & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- XGN
- Stock Information
- Founded
- SGMT 2006
- XGN 2002
- Country
- SGMT United States
- XGN United States
- Employees
- SGMT N/A
- XGN N/A
- Industry
- SGMT
- XGN Medical Specialities
- Sector
- SGMT
- XGN Health Care
- Exchange
- SGMT Nasdaq
- XGN Nasdaq
- Market Cap
- SGMT 131.4M
- XGN 138.3M
- IPO Year
- SGMT 2023
- XGN 2019
- Fundamental
- Price
- SGMT $8.72
- XGN $7.23
- Analyst Decision
- SGMT Strong Buy
- XGN Strong Buy
- Analyst Count
- SGMT 6
- XGN 2
- Target Price
- SGMT $23.17
- XGN $7.50
- AVG Volume (30 Days)
- SGMT 3.2M
- XGN 225.1K
- Earning Date
- SGMT 08-13-2025
- XGN 08-04-2025
- Dividend Yield
- SGMT N/A
- XGN N/A
- EPS Growth
- SGMT N/A
- XGN N/A
- EPS
- SGMT N/A
- XGN N/A
- Revenue
- SGMT N/A
- XGN $56,724,000.00
- Revenue This Year
- SGMT N/A
- XGN $19.39
- Revenue Next Year
- SGMT N/A
- XGN $13.27
- P/E Ratio
- SGMT N/A
- XGN N/A
- Revenue Growth
- SGMT N/A
- XGN 1.78
- 52 Week Low
- SGMT $1.73
- XGN $1.71
- 52 Week High
- SGMT $9.60
- XGN $7.95
- Technical
- Relative Strength Index (RSI)
- SGMT 74.80
- XGN 56.74
- Support Level
- SGMT $6.56
- XGN $7.10
- Resistance Level
- SGMT $9.60
- XGN $7.95
- Average True Range (ATR)
- SGMT 1.13
- XGN 0.51
- MACD
- SGMT 0.29
- XGN -0.04
- Stochastic Oscillator
- SGMT 85.71
- XGN 46.67
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.